Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

ABSTRACT: Data Access Committee EGAC00001003503

PROVIDER: EGAC00001003503 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis.

Project description: Not available

| S-EPMC11502414 | biostudies-literature

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.

Project description: Not available

| S-EPMC6209395 | biostudies-literature

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Project description:Introduction Immune checkpoint blockade (ICB) immunotherapy has revolutionized cancer treatment, demonstrating exceptional clinical responses in a wide range of cancers. Despite the success, a significant proportion of patients still fail to respond, highlighting the existence of unappreciated mechanisms of immunotherapy resistance. Delineating such mechanisms is paramount to minimize immunotherapy failures and optimize the clinical benefit. Methods In this study, we treated tumour-bearing mice with PD-L1 blockage antibody (aPD-L1) immunotherapy, to investigate its effects on cancer-induced emergency myelopoiesis, focusing on bone marrow HSPCs. We examined the impact of aPD-L1 treatment on HSPC quiescence, proliferation, transcriptomic profile, and functionality. Results Herein, we reveal that aPD-L1 in tumour-bearing mice targets the hematopoietic stem and progenitor cells (HSPCs) in the bone marrow (ÃŽÂ’ÃŽÂœ), mediating their exit from quiescence and promoting their proliferation. Notably, disruption of the PDL1/PD1 axis induces transcriptomic reprogramming in HSPCs, observed in both individuals with Hodgkin lymphoma (HL) and tumour-bearing mice, shifting towards an inflammatory state. Furthermore, HSPCs from aPDL1-treated mice demonstrated resistance to cancer-induced emergency myelopoiesis, evidenced by a lower generation of MDSCs compared to control-treated mice. Discussion: Our findings shed light on unrecognized mechanisms of action of ICB immunotherapy in cancer, which involves targeting of BM-driven HSPCs and reprogramming of cancer-induced emergency myelopoiesis.

| EGAS00001007873 | EGA

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer.

Project description: Not available

| S-EPMC7072566 | biostudies-literature

An update on immunotherapy with PD-1 and PD-L1 blockade.

Project description: Not available

| S-EPMC8688791 | biostudies-literature

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives.

Project description: Not available

| S-EPMC7450549 | biostudies-literature

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy.

Project description: Not available